CA2936550C - Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators - Google Patents
Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators Download PDFInfo
- Publication number
- CA2936550C CA2936550C CA2936550A CA2936550A CA2936550C CA 2936550 C CA2936550 C CA 2936550C CA 2936550 A CA2936550 A CA 2936550A CA 2936550 A CA2936550 A CA 2936550A CA 2936550 C CA2936550 C CA 2936550C
- Authority
- CA
- Canada
- Prior art keywords
- oxo
- alkyl
- carbonitrile
- pheny1
- hexahydrobenzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461931291P | 2014-01-24 | 2014-01-24 | |
| US61/931,291 | 2014-01-24 | ||
| PCT/US2015/012579 WO2015112792A1 (en) | 2014-01-24 | 2015-01-23 | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2936550A1 CA2936550A1 (en) | 2015-07-30 |
| CA2936550C true CA2936550C (en) | 2022-07-26 |
Family
ID=52484552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2936550A Active CA2936550C (en) | 2014-01-24 | 2015-01-23 | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9464082B2 (enExample) |
| EP (1) | EP3097089B1 (enExample) |
| JP (1) | JP6530758B2 (enExample) |
| CN (1) | CN107074801B (enExample) |
| CA (1) | CA2936550C (enExample) |
| MX (1) | MX372772B (enExample) |
| TW (1) | TWI670263B (enExample) |
| WO (1) | WO2015112792A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2703274T3 (es) | 2008-04-18 | 2019-03-07 | Reata Pharmaceuticals Inc | Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17 |
| MX339476B (es) | 2008-04-18 | 2016-05-27 | Reata Pharmaceuticals Inc | Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso. |
| DK3444261T3 (da) | 2012-04-27 | 2021-03-08 | Reata Pharmaceuticals Inc | 2,2-difluorpropionamidderivat af bardoxolonmethyl, farmaceutiske sammensætninger og polymorfer deraf til anvendelse ved behandling af visse lidelser |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| TWI649330B (zh) | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法 |
| US11059792B2 (en) | 2015-02-12 | 2021-07-13 | Reata Pharmaceuticals, Inc. | Imidazolyl tricyclic enones as antioxidant inflammation modulators |
| KR20190084310A (ko) | 2016-11-23 | 2019-07-16 | 바이엘 크롭사이언스 악티엔게젤샤프트 | 살충제로서의 2-[3-(알킬술포닐)-2H-인다졸-2-일]-3H-이미다조[4,5-b]피리딘 유도체 및 유사한 화합물 |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| CN112654610B (zh) * | 2018-06-15 | 2024-12-24 | 里亚塔医药公司 | 用于抑制IL-17和RORγ的吡唑和咪唑化合物 |
| EP3810141A1 (en) | 2018-06-20 | 2021-04-28 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
| US20250025465A1 (en) * | 2021-11-17 | 2025-01-23 | Northwestern University | Wt-idh1 inhibition using a covalent and brain-penetrant small molecular inhibitor for ferroptosis induction in high-grade glioma |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1142889A1 (en) * | 2000-04-03 | 2001-10-10 | Pfizer Products Inc. | Pyrazole derivatives as anti-inflammatory/analgesic agents |
| MXPA04002683A (es) * | 2001-09-19 | 2004-06-18 | Pharmacia Corp | Compuestos bencenosulfamida pirazolil sustituidos para el tratamiento de la inflamacion. |
| SMT202000086T1 (it) | 2010-04-12 | 2020-03-13 | Reata Pharmaceuticals Inc | Bardoxolone metile per il trattamento dell'obesità |
| HRP20171859T1 (hr) * | 2010-12-17 | 2018-01-26 | Reata Pharmaceuticals, Inc. | Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale |
-
2015
- 2015-01-23 MX MX2016009589A patent/MX372772B/es active IP Right Grant
- 2015-01-23 CN CN201580015069.4A patent/CN107074801B/zh active Active
- 2015-01-23 CA CA2936550A patent/CA2936550C/en active Active
- 2015-01-23 WO PCT/US2015/012579 patent/WO2015112792A1/en not_active Ceased
- 2015-01-23 US US14/604,129 patent/US9464082B2/en active Active
- 2015-01-23 JP JP2016548158A patent/JP6530758B2/ja active Active
- 2015-01-23 EP EP15705409.9A patent/EP3097089B1/en active Active
- 2015-01-23 TW TW104102426A patent/TWI670263B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2016009589A (es) | 2016-10-28 |
| JP6530758B2 (ja) | 2019-06-12 |
| WO2015112792A1 (en) | 2015-07-30 |
| JP2017503840A (ja) | 2017-02-02 |
| CN107074801A (zh) | 2017-08-18 |
| MX372772B (es) | 2020-06-29 |
| CN107074801B (zh) | 2021-11-05 |
| TW201605808A (zh) | 2016-02-16 |
| CA2936550A1 (en) | 2015-07-30 |
| EP3097089B1 (en) | 2021-02-24 |
| EP3097089A1 (en) | 2016-11-30 |
| US20150225397A1 (en) | 2015-08-13 |
| US9464082B2 (en) | 2016-10-11 |
| TWI670263B (zh) | 2019-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9464082B2 (en) | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | |
| EP2892910B1 (en) | Glycyrrhetinic acid derivatives with anti-inflammatory activity | |
| CA2965981C (en) | Substituted chromanes and method of use | |
| CA3210224A1 (en) | Cdk inhibitors and methods of use thereof | |
| EP2922840B1 (en) | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators | |
| CA2822071C (en) | Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators | |
| JP6139789B2 (ja) | 縮合複素環化合物、その調製方法、医薬組成物及びその使用 | |
| WO2021150806A1 (en) | Heterocyclic compounds as anti-viral agents | |
| CA2956465A1 (en) | Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer | |
| MX2014014658A (es) | Heterociclos capaces de modular las respuestas de los linfocitos t, y métodos de uso de los mismos. | |
| CA2694284A1 (en) | Heterocyclic compounds useful as raf kinase inhibitors | |
| EP3426244A1 (en) | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof | |
| JP2012529525A (ja) | ホスファチジルイノシトール３−キナーゼの阻害薬 | |
| CA3174982A1 (en) | Rsv inhibiting 3-substituted quinoline and cinnoline derivatives | |
| CA3173354A1 (en) | A 2,3-dihydrofuro[2,3-c]pyridine-3-carboxamide compound and its antiviral use | |
| AU2010216219A1 (en) | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase | |
| KR20240121746A (ko) | 테트라하이드로피리다진, 이를 포함하는 조성물, 및 이의 용도 | |
| EP4423067A1 (en) | Sarm1 modulators, preparations, and uses thereof | |
| JP7182548B2 (ja) | アザインデノイソキノリン化合物およびその使用 | |
| EP2488511A1 (en) | Pyrazole inhibitors of phosphatidylinositol 3-kinase | |
| CA3240538A1 (en) | Oxer1 antagonists and uses thereof | |
| WO2022010882A1 (en) | Dihydroquinoxaline and dihydropyridopyrazine derivatives as rsv inhibitors | |
| WO2020210246A1 (en) | Heterocyclic compounds as rsv inhibitors | |
| HK1133873A (en) | 5-(2-furyl)-1, 3-thiazole derivatives useful as inhibitors of phosphatidylinositol 3-kinase | |
| HK1196355A (en) | Compounds useful as inhibitors of choline kinase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200122 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD Year of fee payment: 10 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241223 |